flow trial semaglutide nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential Get With the FLOW! in:
Description
It belongs to a class of drugs that target multiple receptors involved in appetite regulation and glucose metabolism
However, our armamentarium has another option with weight loss medications like Wegovy and Zepbound, also known as GLP-1 receptor agonists
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: the CompoSIT-I Study
Appetite Control and Reduced Cravings Semaglutide affects the parts of your brain that control hunger signals
